Correction: Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients

BMC Cancer

Table 4 HRs and 95% CIs of trajectories on mortality risk

	Model^a	Model^b	Model^c	Model^d
Trajectories groups
Group 1	Reference	Reference	Reference	Reference
Group 2	0.34 (0.16–0.74)†	0.32 (0.15–0.68)†	0.33 (0.14–0.77)‡	0.35 (0.15–0.81)‡
Group 3	0.29 (0.14–0.59)*	0.31 (0.15–0.63)†	0.31 (0.14–0.67)†	0.30 (0.14–0.66)†
Group 4	0.36 (0.13–0.99)‡	0.35 (0.13–0.89)‡	0.41 (0.15–1.09)	0.27 (0.07–1.09)
age		1.03 (1.01–1.05)†	1.03 (1.01–1.05)†	1.03 (1.01–1.05)†
gender		0.81 (0.46–1.42)	0.68 (0.35–1.29)	0.65 (0.33–1.26)
WBC			1.00 (0.99–1.01)	1.00 (0.99–1.01)
Bone marrow blasts			2.79 (0.64–12.09)	3.06 (0.68–13.74)
PLT				1.00 (0.99–1.01)

HRs hazard ratios, CIs confidence intervals; group 1 to group 4 indicate different trajectories of platelets
^aAdjusting for platelet trajectories
^bAdjusting for platelet trajectories, age, gender
^cAdjusting for platelet trajectories, age, gender, WBC, and bone marrow blasts (bone marrow blasts were damaged, causing 12 to be damaged, leaving 137 people in the model, of whom 87 survived and 50 died)
^dAdjusting for platelet trajectories, age, gender, WBC count, bone marrow blasts (bone marrow blasts were damaged, causing 12 to be damaged, leaving 137 people in the model, of whom 87 survived and 50 died.), and PLT
* p<0.001; † p<0.01; ‡ p<0.05

ISSN: 1471-2407